Five-Year Summary

All figures are in US$ million unless stated otherwise

 2019-20 
Constant Currency(1) 		 2019-20 
Reported(2) 		 2018-19 
Reported 		 2017-18 
Reported		 2016-17 
Reported		 2015-16 
Reported 
Total Operating Revenue  9,295  9,151  8,539  7,915  6,947  6,115
Sales Revenue  8,938  8,797  8,205   7,588  6,616  5,909
R&D Investment  933  922  832   702  667  614
Profit before Income Tax Expense  2,741  2,573  2,341   2,281  1,690  1,556
Net profit after tax  2,247  2,103  1,919  1,729  1,337  1,242
Net cash inflow from Operating Activities    2,448  1,644   1,902  1,247  1,179
Capital investment    1,344  1,285   992  861  566
Return on Invested Capital (%)    21.6  24.3   25.9  24.5  26.8(3)
Basic earnings per share ($)    4.633  4.236   3.822  2.937  2.689
Dividend per share ($)    2.02  1.850   1.720  1.360  1.26

(1) Constant currency removes the impact of exchange rate movements, facilitating comparability of operational performance. For further details please refer to CSL’s Financial Statements for the Full Year ended 2019 (Directors’ Report).
(2) The Group’s reported results are in accordance with the Australian Equivalents to International Financial Reporting Standards (A-IFRS).
(3) 2016 figure includes the gain on acquisition of Novartis’ global influenza vaccine business of US$176.1 million.